A simple urine test was found to detect prostate cancer with greater accuracy than the standard PSA (prostate-specific ...

Prostate cancer is a leading cause of cancer-related death among men in the United States. Despite this, widespread adoption ...

Here is how I explain the two tests used for prostate cancer screening to my patients. Traditionally, the DRE has been a standard component of prostate cancer screening. However, current ...

The Global Cancer Vaccines Market is experiencing a significant growth phase, with its valuation rising from $4,188 million in 2019 to an expected $7,303 million by 2027. This rep ...

Telix CEO Christian Behrenbruch hinted changes to the US Food and Drug Administration have hampered approval of its new brain ...

The solid cash conversion allows Telix to internally fund organic growth and flexibility to pursue acquisitions. We expect the company to reinvest the majority of earnings into R&D. We forecast ...

Final 3-year outcome of Focal Ablation versus Radical Prostatectomy (FARP) Randomized Controlled Trial (RCT) presented at 120 th AUA Annual Meeting on Sunday, April 27, 2025.

Myriad Genetics' growth potential lies in its innovative products, strong financials, and expanding market opportunities.

When this therapy is no longer working, prostate cancer is called castration-resistant. On average, people with mCRPC live about two to three years after they are diagnosed. Some may live longer, ...

Bayer now says it expects to make €3 billion in sales for its prostate cancer treatment Nubeqa ... as physicians have more experience with the current drugs. The hike in projected revenues ...

THIS YEAR the Spanish capital, Madrid, provided the backdrop for Europe’s biggest urological event, the 40th Annual European ...

Most prostate cancers eventually stop responding to androgen deprivation therapy (ADT). At this time, the cancers usually are metastatic, meaning the cancer has spread to distant parts of the body.